Santhera Pharmaceuticals Holding AG Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG

SANN

Rang in aandelen #16102
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company,... Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Aandeelprijs
$19.25
Laatst gesynchroniseerd: 2026-10-20
Marktkapitalisatie
$294.54M
Verandering (1 dag)
2.64%
Verandering (1 jaar)
50.03%
Land
CH
Handel Santhera Pharmaceuticals Holding AG (SANN)

Categorie

Healthcare
Dividendrendementgeschiedenis voor Santhera Pharmaceuticals Holding AG (SANN)
Het dividendrendement (TTM) van Santhera Pharmaceuticals Holding AG (aandelsymbool: SANN) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Santhera Pharmaceuticals Holding AG (SANN) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.17%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL